OakChart

LeonaBio Inc

LONAHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

3.88-0.14 (-3.48%)
2026-11-12 05:23 CET
Market cap
36.56 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-141.46 USD m
Free cash flow, TTM
-61.93 USD m
EPS diluted, TTM
-23.11
P/E
-
Compare

Price

LONA against its 20, 50 and 200-day averages
2050200beat
2.505.007.5010.003.2M6.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LONAclose 3.8820-day 4.8050-day 5.51200-day 7.453.8852w low

72.7% under the 52-week high of 14.21 on 18 Mar 2026. 52-week low 2.21 on 28 Sep 2026. Last 15 sessions, 57.5% high to low

Volume 0.16× normal · the line is the 50-bar volume average

Profile

LONA
52-week range, 14% of the way up
2.2114.21

LeonaBio, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Employees19
IPOSep 18, 2020
Beta1.94
ATR, 14d0.58
Rel volume0.16
Short float1.17%
Insider own32.39%
Inst own62.91%

Snapshot

6 groups

Valuation

Index-
Market Cap36.56M
Enterprise Value-13.93M
Income-141.46M
Sales0.00M
Book/sh3.57
Cash/sh5.42
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees19
IPOSep 18, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.09
P/C0.72
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.01
Current Ratio7.01
Debt/Eq0.02
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-23.11
EPS next Y-2.34
EPS next Q-0.69
EPS this Y88.52%
EPS next Y17.47%
EPS next 5Y58.52%
EPS past 3/5Y0.86% -32.09%
Sales past 3/5Y- -
EPS Y/Y TTM-49.65%
Sales Y/Y TTM-
EPS Q/Q55.04%
Sales Q/Q-
EarningsAug 14 AMC
EPS/Sales Surpr.42.40% -

Ownership

Insider Own32.39%
Insider Trans103.22%
Inst Own62.91%
Inst Trans13.44%
ROA-306.05%
ROE-431.39%
ROIC-419.98%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-19.12%
SMA50-29.52%
SMA200-47.91%
Trades-

Technical

Shs Outstand9.42M
Shs Float6.37M
Short Float1.17%
Short Ratio0.37
Short Interest0.07M
52W High14.21 -72.70%
52W Low2.21 75.57%
Volatility14.11% 11.20%
ATR (14)0.58
RSI (14)32.36
Beta1.94
Rel Volume0.16
Avg Volume200.30K
Volume32,981

Performance

Perf Week-15.01%
Perf Month-39.66%
Perf Quarter-50.70%
Perf Half Y-62.40%
Perf YTD-48.75%
Perf Year-16.11%
Perf 3Y-73.78%
Perf 5Y-97.63%
Perf 10Y-
Recom1.00
Target Price16.67
Prev Close4.02
Price3.88
Change %-3.48%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 30, 2026UpgradeCCitizensMkt Perform → Mkt Outperform$18+363.9%
May 27, 2026InitiatedPPiper SandlerOverweight$20+415.5%
Feb 26, 2026InitiatedCCantor FitzgeraldOverweight
Feb 19, 2026UpgradeMMizuhoNeutral → Outperform$10+157.7%
Sep 19, 2024DowngradeMMizuhoOutperform → Neutral$5 → $0.50-87.1%
Sep 04, 2024DowngradeRRodman & RenshawBuy → Neutral
Sep 04, 2024DowngradeJJMP SecuritiesMkt Outperform → Mkt Perform
Sep 04, 2024DowngradeBBTIG ResearchBuy → Neutral
Aug 19, 2024InitiatedRRodman & RenshawBuy$22+467.0%
Oct 17, 2022UpgradeJJMP SecuritiesMkt Perform → Mkt Outperform$20+415.5%

Peers

Mkt cap
TickerCompanyMkt cap
OLMAOlema Pharmaceuticals Inc703.48M
ARVNArvinas Inc452.51M
ATOSAtossa Therapeutics Inc20.26M
CLNNClene Inc60.40M
CELCCelcuity Inc3.16B
COYACoya Therapeutics Inc75.30M
PMNProMIS Neurosciences Inc33.72M
RLAYRelay Therapeutics Inc4.36B
GLSIGreenwich LifeSciences Inc236.17M
INMBINmune Bio Inc34.05M

Insider trading

latest 14 of 23
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Portman David J.10% OwnerOct 26 '26Buy4.963,149,47015,621,3713,149,470Oct 28 08:43 PM
PERCEPTIVE ADVISORS LLCDirectorOct 26 '26Option Exercise0.00776,648777776,648Oct 26 04:00 PM
Litton Mark JamesPRESIDENT and CEOMar 03 '26Option Exercise0.0022,254063,082Mar 05 07:14 PM
Litton Mark JamesPRESIDENT and CEOMar 04 '26Sale5.375,15627,68857,926Mar 05 07:14 PM
Renninger RobertCHIEF FINANCIAL OFFICERMar 03 '26Option Exercise0.003,900016,757Mar 05 07:10 PM
Renninger RobertCHIEF FINANCIAL OFFICERMar 04 '26Sale5.379064,86515,851Mar 05 07:10 PM
Worthington MarkGENERAL COUNSEL and CCOMar 03 '26Option Exercise0.005,726019,704Mar 05 07:06 PM
Worthington MarkGENERAL COUNSEL and CCOMar 04 '26Sale5.371,3287,13118,376Mar 05 07:06 PM
CHURCH KEVINCHIEF SCIENTIFIC OFFICERMar 03 '26Option Exercise0.005,856026,537Mar 05 07:02 PM
CHURCH KEVINCHIEF SCIENTIFIC OFFICERMar 04 '26Sale5.371,3597,29825,178Mar 05 07:02 PM
San Martin JavierCHIEF MEDICAL OFFICERMar 03 '26Option Exercise0.007,418017,607Mar 05 06:59 PM
San Martin JavierCHIEF MEDICAL OFFICERMar 04 '26Sale5.371,7209,23615,887Mar 05 06:59 PM
Mark James LittonOfficerMar 04 '26Proposed Sale5.365,15627,662Mar 04 07:47 PM
San Martin JavierCHIEF MEDICAL OFFICERDec 31 '25Option Exercise0.004,667011,833Jan 05 07:52 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
SURISimplify Propel Opportunities ETFAUM: 74.30M
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B

News

latest 14 of 200
  • LeonaBio to Participate in Cantor Global Healthcare Conference 2026 (GlobeNewswire)
  • LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances (InvestorsHub)
  • LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast Cancer (GlobeNewswire)
  • LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit (GlobeNewswire)
  • LeonaBio to Participate in Upcoming Medical and Industry Meetings in June (GlobeNewswire)
  • LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. (GlobeNewswire)
  • LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer (GlobeNewswire) -5.90%
  • Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio's Data (GlobeNewswire)
  • LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) +7.20% -7.33%
  • LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer (GlobeNewswire)
  • Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" (GlobeNewswire) -6.12%
  • Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million (GlobeNewswire) +62.52%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.800-1.389-0.8010.000.002
2026Q12026-05-07-1.730-2.277-1.7320.000.002
2025Q42026-03-26-18.920-1.351-18.9020.000.002
2025Q32025-11-06-1.680-1.060-1.6760.000.002
2025Q22025-08-07-1.800-1.533-1.7820.000.003
2025Q12025-05-09-2.300-2.400-2.3420.00-1
2024Q42025-02-27-3.800-3.800-3.8580.000.003
2024Q32024-11-07-7.500-7.017-7.4620.000.006
2024Q22024-08-01-7.000-7.370-6.9980.000.006
2024Q12024-05-15-6.900-7.989-6.8730.000.005
2023Q42024-02-22-7.100-8.377-7.1590.000.006
2023Q32023-11-09-8.700-8.145-8.6640.000.005
2023Q22023-08-10-7.800-7.841-7.7890.000.006
2023Q12023-05-11-7.300-6.231-7.3360.000.005
2022Q42023-03-23-7.900-6.540-7.9680.000.006
2022Q32022-11-10-5.300-6.381-5.3390.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-16.700-18.133-6.1430.000.00
2021FY-14.900-15.875-14.8570.000.00
2022FY-25.300-24.053-25.3460.000.00
2023FY-30.900-31.792-30.9500.000.00
2024FY-25.200-25.100-25.1920.000.00
2025FY-24.700-2.895-24.7000.000.00
2026FY--2.835--0.00
2027FY--2.340--0.00
2028FY--1.763--8.27
2029FY--1.810--42.10
2030FY--0.870--121.95

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-174000.000.000.00
2026Q3S2026-08-161000.000.000.00
2026Q3S2026-08-153000.000.000.00
2026Q3S2026-08-143000.000.000.00
2026Q3S2026-05-263000.000.000.00
2026Q3S2026-05-082000.000.000.00
2026Q3S2026-03-271000.000.000.00
2026Q3S2026-02-251000.000.000.00
2026Q3R2026-10-31100-0.75-0.75-0.75
2026Q3R2026-08-17110-0.75-0.75-0.75
2026Q3R2026-08-16100-0.91-0.91-0.91
2026Q3R2026-08-15100-0.91-0.91-0.91
2026Q3R2026-08-14100-0.91-0.91-0.91
2026Q3R2026-07-22100-0.91-0.91-0.91

Estimate history

EPS, annual-1.64-1.66-6.143-14.857-25.346-30.95-25.192-24.7-23.1114
Period20182019202020212022202320242025TTM
EPS, quarterly-6.998-7.462-3.858-2.342-1.782-1.676-18.902-1.732-0.801
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual3.1093.1093.2493.7383.7883.8173.9049.3369.422
Period20182019202020212022202320242025MRQ
Shares, quarterly3.8443.8673.9043.9043.9443.9449.3369.3949.422
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.940.970.970.971.050.482.000.000.00
Gross Profit-0.94-0.97-0.97-0.97-1.05-0.48-2.000.000.00
Selling, General and Administrative Excl. Other53.8333.2195.81126.1292.9763.5418.005.455.01
Research and Development32.5616.5369.7192.8260.6242.3111.293.793.59
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-54.77-34.18-96.78-127.09-94.02-64.02-20.00-5.45-5.01
Interest Expense0.000.000.000.000.000.000.370.350.01
Unusual Expense88.2372.674.13-1.6310.000.001.040.170.16
Net Income Before Taxes-141.46-105.61-96.94-117.67-95.64-54.85-19.95-5.16-5.10
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-141.46-105.61-96.94-117.67-95.64-54.85-19.95-5.16-5.10
Net Income From Continuing Operations-141.46-105.61-96.94-117.67-95.64-54.85-19.95-5.16-5.10
Net Income-141.46-105.61-96.94-117.67-95.64-54.85-19.95-5.16-5.10
EPS (Recurring)-3.36-12.80-24.44-31.25-23.49-14.86-5.92-1.62-1.60
EPS (Basic, Before Extraordinaries)-23.11-24.70-25.19-30.95-25.35-14.86-6.14-1.66-1.64
EPS (Diluted)-23.11-24.70-25.19-30.95-25.35-14.86-6.14-1.66-1.64
EBITDA-53.83-33.21-95.81-126.12-92.97-63.54-18.00-5.45-5.01
Non-Operating Income (Expense)1.551.243.967.798.389.171.450.810.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.716.1011.0510.6210.614.620.630.250.20
Shares Outstanding9.429.343.903.823.793.743.253.113.11
Market Capitalization36.5636.5622.9192.47119.88487.051,112.641,015.00-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.230.230.240.240.200.240.240.24
Gross Profit-0.23-0.23-0.24-0.24-0.20-0.24-0.24-0.24
Selling, General and Administrative Excl. Other19.0517.9110.236.637.099.2915.3225.25
Research and Development12.4711.036.472.583.464.069.1317.68
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-19.28-18.14-10.48-6.87-7.29-9.54-15.57-25.49
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.1715.3972.670.000.00-0.004.13
Net Income Before Taxes-19.01-32.95-82.89-6.61-6.97-9.14-15.00-28.74
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-19.01-32.95-82.89-6.61-6.97-9.14-15.00-28.74
Net Income From Continuing Operations-19.01-32.95-82.89-6.61-6.97-9.14-15.00-28.74
Net Income-19.01-32.95-82.89-6.61-6.97-9.14-15.00-28.74
EPS (Recurring)-0.80-1.17-7.30-1.68-1.78-2.34-3.86-6.71
EPS (Basic, Before Extraordinaries)-0.80-1.73-18.90-1.68-1.78-2.34-3.86-7.46
EPS (Diluted)-0.80-1.73-18.90-1.68-1.78-2.34-3.86-7.46
EBITDA-19.05-17.91-10.23-6.63-7.09-9.29-15.32-25.25
Non-Operating Income (Expense)0.450.590.260.260.330.390.560.88
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.180.661.461.411.601.642.232.94
Shares Outstanding9.429.399.343.943.943.903.903.87
Market Capitalization36.5695.9729.8616.3311.9111.1222.9117.25

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments88.3351.27147.42200.34253.76184.682.064.82
Short Term Receivables0.000.001.631.232.341.300.010.01
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets1.133.575.685.964.706.360.100.07
Total Current Assets89.4654.84154.73207.53260.80192.342.164.90
Net Property, Plant & Equipment2.013.254.445.325.223.580.000.00
Total Investments and Advances0.630.630.6345.2565.9483.510.000.00
Long-Term Note Receivable-----0.000.030.04
Intangible Assets------0.000.00
Deferred Tax Assets112.86-------
Other Assets0.060.060.450.060.060.130.000.00
Total Assets205.0158.78160.25258.15332.01279.562.194.93
Short Term Debt Incl. Current Port. of LT Debt0.470.410.370.330.290.120.000.00
Accounts Payable4.590.320.132.500.571.160.420.12
Other Current Liabilities42.4512.4028.3418.608.443.120.850.45
Total Current Liabilities47.5013.1328.8421.439.294.411.270.57
Long Term Debt0.340.801.221.581.630.881.550.72
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities112.86-------
Other Liabilities16.520.000.000.000.000.002.041.48
Total Liabilities177.2213.9430.0623.0210.925.284.862.77
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.0017.0517.05
Common Equity27.7944.84130.19235.14321.08274.28-19.72-14.89
Total Shareholders Equity27.7944.84130.19235.14321.08274.28-2.672.16
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity27.7944.84130.19235.14321.08274.28-2.672.16
Total Liabilities & Stockholders Equity205.0158.78160.25258.15332.01279.562.194.93
Book Value Per Share2.9811.4934.1162.0885.9084.43-6.34-4.79
Tangible Book Value Per Share2.9811.4934.1162.0885.9084.43-6.34-4.79
Full-Time Employees19266764352215-
Price to Book Ratio1.090.510.600.461.524.063.91-
Return on Assets-80.07-88.52-56.25-32.41-17.94-14.16-144.93-
Return on Equity-290.81-110.77-64.42-34.39-18.43-14.69--
Return on Invested Capital-375.46-212.38-89.55-40.40-17.00-7.25--176.61
Quick Ratio1.884.185.379.6828.0743.661.708.56
Current Ratio1.884.185.379.6828.0743.661.708.56

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-141.46-105.61-96.94-117.67-95.64-54.85-19.95-5.16-5.10
Depreciation0.940.970.970.971.050.48---
Other Funds (Non Cash)94.1878.2810.789.4210.185.122.290.770.37
Funds from Operations-46.33-26.35-85.19-107.28-84.41-49.26-17.67-4.39-4.73
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-15.60-19.38-11.986.5311.946.16-6.450.680.24
Cash from Operating Activities-61.93-45.73-97.17-100.75-72.47-43.10-24.11-3.71-4.48
Capital Expenditures0.000.00-0.03-0.30-1.14-1.57-2.320.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-8.19-15.8954.8695.3958.80-2.51-207.781.502.00
Purchase of Investments-52.21-37.64-14.13-27.67-95.29-299.20-226.84-0.99-5.25
Sale Or Maturity of Investments44.0221.7569.00123.06154.09296.6919.052.507.25
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.040.010.01
Cash from Investing Activities-8.19-15.8954.8395.0957.66-4.08-210.071.512.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock82.5582.460.190.490.6597.09291.090.070.11
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock82.5582.460.190.490.6597.09291.090.070.11
Proceedsfrom Stock Options82.4082.420.000.000.0096.76290.440.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.001.660.871.35
Change in Long Term Debt0.000.000.000.000.000.001.660.871.35
Issuance of Long Term Debt0.000.000.000.000.000.001.660.871.35
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities82.5582.460.190.490.6597.09292.750.951.46
Net Change in Cash12.4420.84-42.15-5.17-14.1549.9158.57-1.26-1.01
Free Cash Flow-61.93-45.73-97.20-101.06-73.61-44.67-26.43-3.71-4.48
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments51.0767.6888.3325.2329.8236.67
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.741.521.131.802.403.18
Total Current Assets54.8169.2089.4627.0232.2239.85
Net Property, Plant & Equipment1.401.702.012.322.632.94
Total Investments and Advances0.630.630.630.630.630.63
Deferred Tax Assets--112.86---
Other Assets0.060.060.060.060.060.09
Total Assets56.8971.59205.0130.0335.5543.51
Short Term Debt Incl. Current Port. of LT Debt0.490.480.470.450.440.43
Accounts Payable2.421.764.590.270.170.87
Other Current Liabilities4.914.4242.452.072.374.20
Total Current Liabilities7.826.6747.502.792.985.49
Long Term Debt0.090.210.340.460.580.69
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--112.86---
Other Liabilities15.4015.4116.520.000.000.00
Total Liabilities23.3022.29177.223.253.566.18
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity33.5949.3027.7926.7931.9937.33
Total Shareholders Equity33.5949.3027.7926.7931.9937.33
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity33.5949.3027.7926.7931.9937.33
Total Liabilities & Stockholders Equity56.8971.59205.0130.0335.5543.51
Book Value Per Share3.575.252.986.798.119.56
Tangible Book Value Per Share3.575.252.986.798.119.56
Full-Time Employees--19---
Price to Book Ratio1.093.451.110.510.370.30
Return on Assets-306.05-224.87-80.07-64.88-81.54-90.12
Return on Equity-431.39-298.76-290.81-89.42-103.80-110.70
Return on Invested Capital-56.43-66.54-294.69-24.26-21.39-24.05
Quick Ratio7.0110.381.889.7010.817.26
Current Ratio7.0110.381.889.7010.817.26

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-19.01-32.95-82.89-6.61-6.97-9.14
Depreciation0.230.230.240.240.240.24
Other Funds (Non Cash)3.2015.8773.701.411.541.64
Funds from Operations-15.58-16.85-8.95-4.96-5.19-7.26
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.38-4.05-10.450.29-1.81-7.40
Cash from Operating Activities-16.96-20.90-19.40-4.67-7.00-14.66
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments16.33-15.54-14.645.650.44-7.35
Purchase of Investments-10.22-20.61-18.04-3.34-6.07-10.20
Sale Or Maturity of Investments26.565.083.408.996.512.85
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities16.33-15.54-14.645.650.44-7.35
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.110.0082.440.000.020.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.110.0082.440.000.020.00
Proceedsfrom Stock Options0.000.0082.42-0.020.020.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.110.0082.440.000.020.00
Net Change in Cash-0.51-36.4448.400.99-6.53-22.02
Free Cash Flow-16.96-20.90-19.40-4.67-7.00-14.66

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.17%0.1M6.4M194.46K
2026-10-151.37%0.1M6.4M186.69K
2026-09-300.30%0.0M6.4M72.55K
2026-09-150.37%0.0M6.4M42.78K
2026-08-310.63%0.0M6.4M34.97K
2026-08-140.61%0.0M6.4M28.57K
2026-07-310.57%0.0M7.2M32.89K
2026-07-150.75%0.1M7.2M36.04K
2026-06-300.78%0.1M7.2M33.34K
2026-06-150.72%0.1M7.2M53.68K
2026-05-290.79%0.1M7.2M58.87K
2026-05-150.86%0.1M7.2M62.19K
2026-04-300.80%0.1M7.2M62.98K
2026-04-151.09%0.1M7.2M66.88K
2026-03-311.37%0.1M7.3M77.07K
2026-03-130.61%0.0M7.2M1.09M
2026-02-270.51%0.0M7.2M1.07M
2026-02-130.43%0.0M7.2M1.06M
2026-01-300.48%0.0M7.2M1.06M
2026-01-150.78%0.1M7.2M1.04M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-04SCHEDULE 13GSEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-28SCHEDULE 13D/ASEC
2026-10-26SCHEDULE 13D/ASEC
2026-10-264Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-09-228-KCurrent report2026-09-18SEC
2026-09-033Initial statement of beneficial ownership of securities2026-08-24SEC
2026-08-31SCHEDULE 13DSEC
2026-08-268-KCurrent report2026-08-26SEC
2026-08-25SCHEDULE 13D/ASEC
2026-08-20SCHEDULE 13G/ASEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-04-09SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-238-KCurrent report2026-06-22SEC
2026-05-15SCHEDULE 13GSEC
2026-05-11ARSAnnual report to security holders. 2025-12-31SEC
2026-05-11DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-11DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-22SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1015.62M100
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030056.22K5
2026-020000
2026-010043.20K5
2025-120000
2025-110000

Institutional holders

Manager% owned
PERCEPTIVE ADVISORS LLC19.79%
Kalehua Capital Management LLC8.38%
ADAR1 Capital Management, LLC8.27%
ACORN CAPITAL ADVISORS, LLC6.76%
Commodore Capital LP4.94%
TCG Crossover Management, LLC4.94%
NEA Management Company, LLC4.94%
Spruce Street Capital LP4.19%
Blackstone Inc.3.46%
ADAGE CAPITAL PARTNERS GP, L.L.C.3.19%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.95%
Simplify Propel Opportunities ETF1.59%
VANGUARD EXTENDED MARKET INDEX FUND0.88%
Fidelity Extended Market Index Fund0.38%
iShares Micro-Cap ETF0.23%
Fidelity Total Market Index Fund0.13%
Fidelity Series Total Market Index Fund0.11%
Fidelity Nasdaq Composite Index Fund0.08%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.06%
U.S. MICRO CAP PORTFOLIO0.04%

OakChart. LONA. Cached 15 minutes.